A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
Jianbiao Zhou(National University Cancer Institute, Singapore), Wee Joo Chng(National University Health System)
Cited by 39
Related Papers
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
|Blood|2011|212
Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia
|Journal of Hematology & Oncology|2017|75